Nutritional supplement for use under physiologically stressful conditions

Information

  • Patent Grant
  • 8263667
  • Patent Number
    8,263,667
  • Date Filed
    Tuesday, March 8, 2011
    13 years ago
  • Date Issued
    Tuesday, September 11, 2012
    12 years ago
Abstract
A nutritional supplement for use in physiologically stressful conditions is disclosed. The nutritional supplement may include one or more of vitamin A, vitamin E, vitamin D3, vitamin C, vitamin B1, riboflavin, niacin, folic acid, vitamin B6, biotin, pantothenic acid, vitamin B12, magnesium, zinc, selenium, chromium, copper, iron, alpha lipoic acid, lutein and lycopene.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


Embodiments of the present invention generally relate to nutritional supplements and in particular to nutritional supplements for use under physiologically stressful conditions.


2. Description of the Related Art


Physiological responses to stressful conditions are generally the same; only the intensity of the response and whether or not any given response will be evoked are individual in nature. Acute stressful situations, such as resulting from a trauma, produce a physiological response, after which the body returns to its normal, un-stressful state. When the body enters a stressful situation, the sympathetic nervous system invokes a fight or flight response. Once the stressful stimuli have been removed, the parasympathetic nervous system returns the body to a normal state.


Chronic stressful conditions, caused by for example a divorce, an unpleasant boss, lack of money, or building a new home, are more insidious. The physiological response endures and the body fails to return to the baseline state. Being in a continuous state of stress, an individual will feel unwell, partly because the mechanisms that ordinarily help overcome stress have become exhausted. That is, the parasympathetic nervous system is unable to return the body to a “normal” state.


Symptoms classically seen in a stressful situation include an increase in heart rate, blood pressure, sweating, metabolic rate and peristaltic activity. These symptoms can be alleviated by inducing the body to return to its normal resting state.


Thus, there is a need for a nutritional supplement to alleviate or at least reduce the stress and symptoms associated therewith.


SUMMARY OF THE INVENTION

Embodiments of the present invention generally relate to nutritional supplements and in particular to nutritional supplements for use under physiologically stressful conditions.


In one embodiment, a pharmaceutically-acceptable single-dosage formulation consists essentially of between about 150 mg to about 450 mg of vitamin C; between about 600 IUs to about 1800 IUs of vitamin D3; between about 75 IUs to about 150 IUs of vitamin E; between about 15 mg to about 35 mg of vitamin B1; between about 1.7 mg to about 5.1 mg of vitamin B2; between about 20 mg to about 50 mg of niacin; between about 20 mg to about 50 mg of vitamin B6; between about 0.5 mg to about 2.5 mg of folate; between about 35 mcg to about 105 mcg of vitamin B12; between about 2.5 mg to about 7.5 mg of pantothenic acid; between about 150 mcg to about 450 mcg of biotin; between about 50 mg to about 100 mg of calcium; between about 15 mg to about 55 mg of magnesium; between about 15 mg to about 55 mg of zinc; between about 0.5 to about 1.5 mg of copper; between about 75 mcg to about 175 mcg of selenium; between about 75 mcg to about 225 mcg of chromium; between about 10 mg to about 40 mg of alpha lipoic acid; between about 20 mg to about 50 mg of co-enzyme Q-10; between about 1 mg to about 3 mg of lutein; between about 250 mcg to about 750 mcg of lycopene; between about 2.5 mg to about 7.5 mg of pepper extract; and at least one or more excipients.


In another embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists of between about 150 mg to about 450 mg of ascorbic acid; between about 600 IUs to about 1800 IUs of cholecalciferol; between about 75 IUs to about 150 IUs of d-alpha tocopherol succinate; between about 15 mg to about 35 mg of thiamine mononitrate; between about 1.7 mg to about 5.1 mg of riboflavin; between about 20 mg to about 50 mg of niacinamide; between about 20 mg to about 50 mg of pyridoxine hcl; between about 0.5 mg to about 2.5 mg of folic acid; between about 35 mcg to about 105 mcg of cyanocobalamin; between about 2.5 mg to about 7.5 mg of d-calcium pantothenate; between about 150 mcg to about 450 mcg of d-biotin; between about 50 mg to about 100 mg of dicalcium malate; between about 15 mg to about 55 mg of dimagnesium malate; between about 15 mg to about 55 mg of zinc bisglycinate chelate; between about 0.5 to about 1.5 mg of copper amino acid chelate; between about 75 mcg to about 175 mcg of selenium amino acid chelate; between about 75 mcg to about 225 mcg of chromium amino acid chelate; between about 10 mg to about 40 mg of alpha lipoic acid; between about 20 mg to about 50 mg of co-enzyme Q-10; between about 1 mg to about 3 mg of lutein; between about 250 mcg to about 750 mcg of lycopene; between about 2.5 mg to about 7.5 mg of pepper extract; and at least one or more excipients.


In yet another embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists of between about 150 mg to about 450 mg of ascorbic acid; between about 600 IUs to about 1800 IUs of cholecalciferol; between about 75 IUs to about 150 IUs of d-alpha tocopherol succinate; between about 15 mg to about 35 mg of thiamine mononitrate; between about 1.7 mg to about 5.1 mg of riboflavin; between about 20 mg to about 50 mg of niacinamide; between about 20 mg to about 50 mg of pyridoxine hcl; between about 0.5 mg to about 2.5 mg of folic acid; between about 35 mcg to about 105 mcg of cyanocobalamin; between about 2.5 mg to about 7.5 mg of d-calcium pantothenate; between about 150 mcg to about 450 mcg of d-biotin; between about 50 mg to about 100 mg of dicalcium malate; between about 15 mg to about 55 mg of dimagnesium malate; between about 15 mg to about 55 mg of zinc bisglycinate chelate; between about 0.5 to about 1.5 mg of copper amino acid chelate; between about 75 mcg to about 175 mcg of selenium amino acid chelate; between about 75 mcg to about 225 mcg of chromium amino acid chelate; between about 10 mg to about 40 mg of alpha lipoic acid; between about 20 mg to about 50 mg of co-enzyme Q-10; between about 1 mg to about 3 mg of lutein; between about 250 mcg to about 750 mcg of lycopene; between about 2.5 mg to about 7.5 mg of pepper extract; between about 100 mg to about 300 mg of dicalcium phosphate; between about 25 mg to about 75 mg of microcrystalline cellulose; between about 10 mg to about 30 mg of stearic acid; between about 10 mg to about 30 mg of croscarmellose sodium; between about 5 mg to about 15 mg of magnesium trisillicate; between about 5 mg to about 15 mg of magnesium stearate; and between about 5 mg to about 15 mg of hydroxypropyl methylcellulose; wherein the single-dosage formulation comprises at one of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, an effervescent tablet, a hard gelatin capsule, a soft gelatin capsule, a liquid suspension or a food product.







DETAILED DESCRIPTION

It is understood that the embodiments of the present invention are not limited to the particular methodologies, protocols, solvents and reagents, and the like, described herein as they may vary. It is also to be understood the terminology used herein is used for the purpose of describing particular embodiments only and not intended to limit the scope of the present invention. It must also be noted that as used herein and in the appended claims, the singular form “a,” “an” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a vitamin” is a reference to one or more vitamins and includes equivalents thereof know to those skilled in the art and so forth.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skilled in the art to which this invention belongs. Preferred methods, devices and materials are described, although any methods and materials similar or equivalent to those described herein could be used in the practice or testing of the present invention. All references cited herein are incorporated by reference herein in there entirety.


The term “disease state” as used herein, may comprise any state in which one or more organs or components of an organism malfunction. The term includes “disease state” may refer to any deterioration of any component of a body. The term “disease state” may refer to any deficiency of any compound necessary for the maintenance or function of any component of any organism. The term “disease state” may refer to any condition in which a body contains toxins, produced by microorganisms that infect the body or by body cells through faulty metabolism or absorbed from an external source.


The term “disease states” may be adverse states caused by any diet, any virus, or any bacteria. “Disease states” may comprise disorders associated with pregnant females such as for example, osteomalacia and preeclampsia and disorders associated with a fetus such as, for example, neurotube defects and various fetal abnormalities. “Disease states” may comprise any pulmonary disorder such as, for example, bronchitis, bronchiectasis, atelectasis, pneumonia, diseases caused by inorganic dust, diseases caused by organic dust, any pulmonary fibrosis, and pleurisy. “Disease states” may comprise any hematological/oncological disorders such as, for example, anemia, hemophilia, leukemia, lymphoma.


A “disease state” may comprise any cancer such as, for example, breast cancer, lung cancer, prostate cancer, pancreatic cancer, liver cancer, stomach cancer, testicular cancer, ovarian cancer, skin cancer, cancer of the brain, cancer of the mouth, cancer of the throat, and cancer of the neck. “Disease states” may comprise any disorder of the immune system such as, for example, Acquired Immune Deficiency Syndrome (AIDS), AIDS-related complex, infection by any strain of any Human Immunodeficiency Virus (HIV), and other viruses and pathogens such as bacteria.


A “disease state” may comprise any cardiovascular disorders such as, for example, arterial hypertension, orthostatic hypotension, arteriolosclerosis, coronary artery disease, cardiomyopathy, any arrhythmia, any valvular heart disease, endocarditis, pericardial disease, any cardiac tumor, any aneurism, and any peripheral vascular disorder. “Disease states” may comprise any hepatic/biliary disorders such as, for example, jaundice, hepatic steatosis, fibrosis, cirrhosis, hepatitis, any hepatic granuloma, any liver tumor, cholelithiasis, cholecystitis, and choledocholithiasis.


The term “physiologically stressful state,” as used herein, comprises any state of an organism in which the organism faces one or more physiological challenges. A “physiologically stressful state” may comprise pre-pregnancy, pregnancy, lactation, or conditions in which an organism faces physiological challenges related to for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins. A “physiologically stressful state” may result from one or more disease states.


The term “subject” as used herein comprises any and all organisms and includes the term “patient.” “Subject” may refer to a human or any other animal. “Subject” may also refer to a fetus.


Embodiments of the present invention relate to a nutritional supplement, which contains active ingredients to relieve an individual in a physiological stressful condition. One embodiment of the present invention assembles clinically proven food-grade nutrients in efficacious doses shown to relieve the symptoms of physiological stressful conditions. Specifically, the nutritional supplement comprises fat-soluble and water-soluble vitamins as well as essential minerals, in certain amounts, to reduce physiological stressful conditions associated with the individual as discussed below.


Physiological responses to physiological stressful conditions are the same regardless of the causation. Under stressful situations, the body releases neurotransmitters (e.g., epinephrine, norepinephrine and serotonin) and cortisol to bring the body back to a non-stressed state. In a chronically stressed situation, the neurotransmitters can become depleted and as a result, the lack of serotonin is directly related to poor mood and depression. Cortisol, however, does not get depleted and its continued presence in the body depresses mood. Long-term exposure to cortisol leads to impaired memory, depressed immune function, chronic obesity and development of chronic disease.


The nutritional supplement can be made in a variety of forms such as a pharmaceutical composition (e.g., table, powder, suspension, liquid, capsule, and jel), nutritional beverages, puddings, confections (i.e., candy), ice cream, frozen confections and novelties, or non-baked extruded food such as bars to assist patients with stressful conditions and the management thereof. The nutritional supplement can be formulated into a snack to be taken as part of a diet or it can be formulated as a meal replacement. For a snack and meal replacement, nutritional supplements should provide from about 50 to about 400 kcal per serving.


For purposes of the present invention, an embodiment of the nutritional supplement comprises the components described about as a single serving (serving unit), whereby one or a plurality (in one embodiment: two) of these supplements is (are) consumed daily. The proportions of these N ingredients are based on about 60 to about 75-gram serving. The preferred form of administration is in tablet form but the supplement could be consumed as a nutritional bar or as a liquid.


In an embodiment, each serving contains 220 kcal and is comprised of macro nutrient percentages in concert with the dietary recommendation of the American Diabetic Association and American Dietary Association. Other serving sizes are contemplated by the present invention. The total amount of each ingredient should be appropriately adjusted.


The ingredients that make up the nutritional supplement are described in detail below with regard to their relative role each contributes to the therapeutic advantages of the present invention.


Vitamin E, a fat-soluble vitamin, is an antioxidant vitamin involved in the metabolism of all cells. It protects vitamin A and essential fatty acids from oxidation in the body cells and prevents breakdown of body tissues. Embodiments of the present invention may comprise between about 75 IUs to about 150 IUs of vitamin E, and in one embodiment, about 125 IUs of vitamin E are provided. In one exemplary embodiment, vitamin E is provided in the form of d-alpha tocopherol succinate.


Vitamin D3 is a naturally occurring bodily substance that many believe exert a protective effect in multiple sclerosis—both in the development of the disease and in limiting its progression. It is naturally produced in the skin in response to sunlight but is also present in certain foodstuffs (particularly oily fish). Vitamin D3 is a type of steroid hormone and among other things, a powerful mediator of immune function.


Vitamin D3 is best known for its effect on calcium metabolism. Proper levels are necessary to maintain bone mineral density and serum (blood) calcium levels. This is especially true among the very young where it is used to treat rickets and in combination with vitamin A for the treatment of osteoporosis in the elderly, particularly post menopausal women who are often subject to fractures due to loss of bone density.


In studies, vitamin D3 has been found helpful against autoimmunity for the down-regulation of Th1 and up-regulation of Th2 cells. It has also been shown to regulate the neurotrophins NGF (Nerve Growth Factor), NT-3 (NeuroTrophin 3) and NT-4. In addition, vitamin D3 has also been found to promote differentiation and cell death in neuroblastoma (brain tumor) cell lines as well as cancers in general.


Embodiments of the present invention may comprise between about 600 IUs to about 1800 IUs of vitamin D3, and in one embodiment, about 1200 IUs of vitamin D3 are provided. In one exemplary embodiment, vitamin D3 is provided in the form of cholecalciferol.


Vitamin C is a water-soluble, antioxidant vitamin. It is important in forming collagen, a protein that gives structure to bones, cartilage, muscle, and blood vessels. Vitamin C also aids in the absorption of iron, and helps maintain capillaries, bones, and teeth. As a water-soluble antioxidant, vitamin C is in a unique position to “scavenge” aqueous peroxyl radicals before these destructive substances have a chance to damage lipids. It works along with vitamin E, a fat-soluble antioxidant, and the enzyme glutathione peroxidase to stop free radical chain reactions.


Vitamin C can enhance the body's resistance to an assortment of diseases, including infectious disorders and many types of cancer. It strengthens and protects the immune system by stimulating the activity of antibodies and immune system cells such as phagocytes and neutrophils. Vitamin C contributes to a variety of other biochemical functions. These include the biosynthesis of the amino acid carnitine and the catecholamines that regulate the nervous system. It also helps the body to absorb iron and to break down histamine. Although vitamin C is found in every cell, it is especially useful in key parts of the body. These include the blood, the skin, the nervous system, the teeth and bones and glands such as the thymus, adrenals and thyroid.


Embodiments of the present invention may comprise between about 150 mg to about 450 mg of vitamin C, and in one embodiment, about 300 mg of vitamin C are provided. In one exemplary embodiment, vitamin C is provided in the form of ascorbic acid.


Vitamin B1, also known as thiamin, helps fuel your body by converting blood sugar into energy. It keeps the mucous membranes healthy and is essential for nervous system, cardiovascular and muscular function. Vitamin B1 (thiamin) is essential for the metabolism of carbohydrates to produce energy and for normal nerve and heart function. Embodiments of the present invention may comprise between about 15 mg to about 35 mg of vitamin B1, and in one embodiment, about 25 mg of vitamin B1 are provided. In one exemplary embodiment, vitamin B1 is provided in the form of thiamine mononitrate.


Vitamin B2 is a water-soluble vitamin in the B-complex group. Generally, riboflavin, a form of vitamin B2, works with the other B vitamins. It is important for body growth and red blood cell production and helps in releasing energy from carbohydrates. Riboflavin, as flavin mononucleotide or flavin adenine dinucleotide, acts as an essential coenzyme in many oxidation-reduction reactions involved with carbohydrate metabolism. Deficiency results in oral, ocular, cutaneous, and genital lesions. Embodiments of the present invention may comprise between about 1.7 mg to about 5.1 mg of vitamin B2, and in one embodiment, about 3.4 mg of vitamin B2 are provided.


Niacin, or vitamin B3, is required for cell respiration, helps in the release of energy and metabolism of carbohydrates, fats, and proteins, proper circulation and healthy skin, functioning of the nervous system, and normal secretion of bile and stomach fluids. It is used in the synthesis of sex hormones, treating schizophrenia and other mental illnesses, and a memory-enhancer. Niacin given in pharmaceutical dosage improves the blood cholesterol profile, and has been used to clear the body of organic poisons, such as certain insecticides. Embodiments of the present invention may comprise between about 20 mg to about 50 mg of niacin, and in one embodiment, about 35 mg of niacin are provided. In one exemplary embodiment, niacin is provided in the form of niacinamide.


Folate is a water-soluble vitamin in the B-complex group. Generally, folic acid, a form of folate, works along with vitamin B12 and vitamin C to help the body digest and utilize proteins and to synthesize new proteins when they are needed. It is necessary for the production of red blood cells and for the synthesis of DNA. Folic acid also helps with tissue growth and cell function. In addition, it helps to increase appetite when needed and stimulates the formation of digestive acids.


Folic acid supplements may be used in the treatment of disorders associated with folic acid deficiency and may also be part of the recommended treatment for certain menstrual problems and leg ulcers. Embodiments of the present invention may comprise between about 0.5 mg to about 2.5 mg of folate, and in one embodiment, about 1.25 mg of folate are provided.


Vitamin B6 is a water-soluble vitamin that exists in three major chemical forms: pyridoxine, pyridoxal, and pyridoxamine. It performs a wide variety of functions in the body and is essential for good health. For example, vitamin B6 is needed for more than 100 enzymes involved in protein metabolism. It is also essential for red blood cell metabolism. The nervous and immune systems need vitamin B6 to function efficiently, and it is also needed for the conversion of tryptophan to niacin.


The body needs vitamin B6 to make hemoglobin. Hemoglobin within red blood cells carries oxygen to tissues. Vitamin B6 also helps increase the amount of oxygen carried by hemoglobin. A vitamin B6 deficiency can result in a form of anemia that is similar to iron deficiency anemia. Vitamin B6 also helps maintain blood glucose (sugar) within a normal range. When caloric intake is low, the body needs vitamin B6 to help convert stored carbohydrate or other nutrients to glucose to maintain normal blood sugar levels.


Embodiments of the present invention may comprise between about 20 mg to about 50 mg of vitamin B6, and in one embodiment, about 35 mg of vitamin B6 are provided. In one exemplary embodiment, vitamin B6 is provided in the form of pyridoxine.


Biotin, a water-soluble member of the B-vitamin family, is an essential nutrient in human nutrition. It is involved in the biosynthesis of fatty acids, gluconeogenesis, energy production, the metabolism of the branched-chain amino acids (L-leucine, L-isoleucine, L-valine) and the de novo synthesis of purine nucleotides. Research indicates that biotin plays a role in gene expression, both at the transcriptional and translational levels, and that it may also play a role in DNA replication. Biotin is necessary for both metabolism and growth in humans, particularly with reference to production of fatty acids, antibodies, digestive enzymes, and niacin (vitamin B3) metabolism.


Embodiments of the present invention may comprise between about 150 mcg to about 450 mcg of vitamin B1, and in one embodiment, about 300 mcg of biotin are provided. In one exemplary embodiment, biotin is provided in the form of d-biotin.


Pantothenic acid, also known as vitamin B5, is essential for a number of basic bodily functions, from growth to reproduction. It participates in the continual breakdown of carbohydrates, fats, and proteins from food, converting them into compounds the body can use. This vitamin also produces numerous enzymes and helps maintain precise communication between the central nervous system and the brain. Pantothenic acid comes in two forms: calcium pantothenate and pantethine. Calcium pantothenate is widely used for treating ailments from stress to heartburn, while pantethine is mainly recommended for lowering blood cholesterol levels in those who don't respond to other natural treatments.


Embodiments of the present invention may comprise between about 2.5 mg to about 7.5 mg of pantothenic acid, and in one embodiment, about 5 mg of pantothenic acid are provided. In one exemplary embodiment, pantothenic acid is provided in the form of d-calcium pantothenate.


Vitamin B12, a water-soluble vitamin, is also called cobalamin because it contains the metal cobalt. This vitamin helps maintain healthy nerve cells and red blood cells. It is also needed to help make DNA, the genetic material in all cells. Embodiments of the present invention may comprise between about 35 mcg to about 105 mcg of vitamin B12, and in one embodiment, about 70 mcg of vitamin B12 are provided. In one exemplary embodiment, vitamin B12 is provided in the form of cyanocobalamin.


Calcium is an important component of a healthy diet and a mineral necessary for life. Approximately ninety-nine percent of the body's calcium is stored in the bones and teeth. The rest of the calcium in the body has other important uses, such as some exocytosis, especially neurotransmitter release, and muscle contraction. In the electrical conduction system of the heart, calcium replaces sodium as the mineral that depolarizes the cell, proliferating the action potential.


Long-term calcium deficiency can lead to rickets and poor blood clotting and in case of a menopausal woman, it can lead to osteoporosis, in which the bone deteriorates and there is an increased risk of fractures. While a lifelong deficit can affect bone and tooth formation, over-retention can cause hypercalcemia (elevated levels of calcium in the blood), and decreased absorption of other minerals. However, a high calcium intake has been associated with a lower risk for kidney stones. Thus, a proper balance of calcium absorption in the body is requisite for good health.


Embodiments of the present invention may comprise between about 50 mg to about 100 mg of calcium, and in one embodiment, about 75 mg of calcium are provided. In one exemplary embodiment, vitamin B12 is provided in the form of dicalcium malate. In another embodiment, dicalcium malate may be obtained in the form of a supplement, from Albion International, Inc. of Clearfield, Utah, sold under the commercial brand DimaCal®.


Magnesium is the fourth most abundant mineral in the body and is essential to good health. Approximately 50% of total body of magnesium is found in the bone. The other half is found predominantly inside cells of body tissues and organs. Only 1% of magnesium is found in blood, but the body works very hard to keep blood levels of magnesium constant. Magnesium is needed for more than 300 biochemical reactions in the body. It helps maintain normal muscle and nerve function, keeps heart rhythm steady, supports a healthy immune system, and keeps bones strong. Magnesium also helps regulate blood sugar levels, promotes normal blood pressure, and is known to be involved in energy metabolism and protein synthesis. Magnesium may play a role in preventing and managing disorders such as hypertension, cardiovascular disease, and diabetes.


Embodiments of the present invention may comprise between about 15 mg to about 55 mg of magnesium, and in one embodiment, about 35 mg of magnesium are provided. In one exemplary embodiment, magnesium is provided in the form of dimagnesium malate.


Zinc is vital for the healthy working of many of the body's systems. Zinc plays a crucial role in growth and cell division where it is required for protein and DNA synthesis, in insulin activity, in the metabolism of the ovaries and testes, and in liver function. As a component of many enzymes, zinc is involved in the metabolism of proteins, carbohydrates, lipids and energy. Zinc helps with the healing of wounds and is a vital component of many enzyme reactions. It is also important for healthy skin and is essential for a healthy immune system and resistance to infection.


Embodiments of the present invention may comprise between about 15 mg to about 55 mg of zinc, and in one embodiment, about 35 mg of zinc are provided. In one exemplary embodiment, zinc is provided in the form of zinc bisglycinate chelate.


Selenium is a trace mineral essential to good health. Selenium is incorporated into proteins to make selenoproteins, which are important antioxidant enzymes. The antioxidant properties of selenoproteins help prevent cellular damage from free radicals that may contribute to the development of chronic diseases such as cancer and heart disease. Other selenoproteins help regulate thyroid function and play a role in the immune system.


Embodiments of the present invention may comprise between about 75 mcg to about 175 mcg of selenium, and in one embodiment, about 125 mcg of selenium are provided. In one exemplary embodiment, selenium is provided in the form of selenium amino acid chelate.


Chromium is a mineral required in small quantities by the body. It enables insulin to function normally and helps the body metabolize carbohydrates and fats. Picolinate, a by-product of the amino acid tryptophan, is paired with chromium in supplements because it helps the body absorb chromium more efficiently. Embodiments of the present invention may comprise between about 75 mcg to about 225 mcg of chromium, and in one embodiment, about 150 mcg of chromium are provided. In one exemplary embodiment, chromium is provided in the form of chromium amino acid chelate.


Copper is needed for normal growth and health. Copper is also needed to help the body use iron. It is also important for nerve function, bone growth, and to help the body use sugar. Embodiments of the present invention may comprise between about 0.5 mg to about 1.5 mg of copper, and in one embodiment, about 1 mg of copper is provided. In one exemplary embodiment, copper is provided in the form of copper amino acid chelate.


Alpha-lipoic acid, also known as thioctic acid, is a disulfide compound that is a cofactor in vital energy-producing reactions in the body. It is also a potent biological antioxidant in both the fatty and watery regions of cells. Alpha-lipoic acid also plays an important role in the synergism of antioxidants, recycling and extending the metabolic lifespan of vitamin C, glutathione, coenzyme Q10, and vitamin E. Embodiments of the present invention may comprise between about 10 mg to about 40 mg of alpha-lipoic acid, and in one embodiment, about 25 mg of alpha-lipoic acid are provided.


Co-enzyme Q10 is often utilized as a dietary supplement because of its ability to transfer electrons and therefore act as an antioxidant. Supplementation of Co-enzyme Q10 is a treatment for some of the very rare and serious mitochondrial disorders and other metabolic disorders. Coenzyme Q10 is also beneficial in treatment of patients with congestive heart failure, and as a relief from symptoms associated with migraine headaches, cancer treatments (e.g., chemotherapy, radiation, etc.), cardiac arrest, and blood pressure, among others. Embodiments of the present invention may comprise between about 20 mg to about 50 mg of co-enzyme Q10, and in one embodiment, about 35 mg of co-enzyme Q10 are provided.


Lutein is a member of the carotenoid family, a family best known for betacarotene. Lutein is a natural fat-soluble yellowish pigment found in the macula of the human retina, as well as the human crystalline lens. It is thought to play a role in protection against age-related macular degeneration (ARMD) and age-related cataract formation. Lutein may also be protective against some forms of cancer. Embodiments of the present invention may comprise between about 1 mg to about 3 mg of lutein, and in one embodiment, about 2 mg of lutein are provided.


Lycopene is a member of the carotenoid family of chemical substances. Lycopene is a natural fat-soluble pigment and antioxidant that may be beneficial in treating certain disorders, such as prostate cancer and other cancers, coronary heart disease, exercise-induced asthma, macular degeneration, sunburn, atherosclerosis, high cholesterol, and high blood pressure associated with pregnancy. Embodiments of the present invention may comprise between about 250 mcg to about 750 mcg of lycopene, and in one embodiment, about 500 mcg of lycopene are provided.


Natural pepper extract may provide enhanced absorption of nutrients by the digestive system. In many embodiments, a natural pepper extract may comprise an extract from the fruits of piper nigrum L (i.e., household black pepper) or piper longum L (i.e., long pepper). In one exemplary embodiment, the pepper extract comprises an extract manufactured by Sabinsa Corporation, commercially known as Peperine or Bioperine, covered by U.S. Pat. Nos. 5,536,506, 5,544,161, 5,972,382 and 6,054,585, the disclosures of which are incorporated by reference in their entireties. Embodiments of the present invention may comprise between about 2.5 mg to about 7.5 mg of pepper extract, and in one embodiment, about 5 mg of pepper extract are provided.


While the above elements comprise the essential vitamins, minerals and nutrients of embodiments of the present invention, the nutritional supplement can also contain other ingredients, provided such ingredients to not materially or substantially alter the embodiments of the present invention.


In many embodiments of the present invention, the nutritional supplement further comprises at least one or more excipients, or other inactive ingredients, to be used as carriers for the active ingredients of the formulation. In one embodiment, the nutritional supplement may further comprise at least one or more of dicalcium phosphate, microcrystalline cellulose, stearic acid, croscarmellose sodium, magnesium trisillicate, magnesium stearate, hydroxypropyl methylcellulose, or the like.


In certain embodiments, the excipients may be provided to the formulation in amounts of between about 100 mg to about 300 mg of dicalcium phosphate, between about 25 mg to about 75 mg of microcrystalline cellulose, between about 10 mg to about 30 mg of stearic acid, between about 10 mg to about 30 mg of croscarmellose sodium, between about 5 mg to about 15 mg of magnesium trisillicate, between about 5 mg to about 15 mg of magnesium stearate, and between about 5 mg to about 15 mg of hydroxypropyl methylcellulose. In one specific embodiment, the excipients are provided to the formulation in the amounts of about 200 mg of dicalcium phosphate, about 50 mg of microcrystalline cellulose, about 20 mg of stearic acid, about 20 mg of croscarmellose sodium, about 10 mg of magnesium trisillicate, about 10 mg of magnesium stearate and about 10 mg of hydroxypropyl methylcellulose.


In addition to excipients or carriers, other inactive ingredients may also be provided in reasonable amounts, such as flavoring agents, coloring agents, or the like. The amount of the other inactive ingredients per unit serving are a matter of design and will depend upon the total number of unit servings of the nutritional supplement daily administered to the patient. The total amount of other ingredients will also depend, in part, upon the condition of the patient. Preferably the amount of other ingredients will be a fraction or multiplier of the recommended daily allowance (RDA) or RDI (reference daily intake) amounts. For example, nutritional supplements can comprise 50 percent RDI of vitamins and minerals per unit dosage and the patient will consume two units per day.


Flavors, coloring agents, spices, nuts and the like can be incorporated into the product. Flavorings can be in the form of flavored extracts, volatile oils, chocolate flavorings (e.g., non-caffeinated cocoa or chocolate or chocolate substitute such as carob), peanut butter flavoring, cookie crumbs, crisp rice, vanilla or any commercially available flavoring. Flavoring can be protected with mixed tocopherols.


Examples of useful flavorings include but are not limited to pure anise extract, imitation banana extract, imitation cherry extract, chocolate extract, pure lemon extract, pure orange extract, pure peppermint extract, imitation pineapple extract, imitation rum extract, imitation strawberry extract, or pure vanilla extract or volatile oils, such as balm oil, bay oil or bergamots oil, cedar-wood oil, cherry oil, walnut oil, cinnamon oil, clove oil, or peppermint oil; peanut butter, chocolate flavoring, vanilla cookie crumb, butterscotch or toffee.


In an embodiment, nutritional supplement contains berry or other fruit flavors. The food compositions may further be coated, for example with a yogurt coating, if it is produced as a bar.


Emulsifiers may be added for stability of the final product. Examples of suitable emulsifiers include, but are not limited to, lecithin (e.g., from egg or soy), and/or mono-n dye-glycerides. Other emulsifiers are readily apparent to the skilled artesian and selection of suitable emulsifiers will depend, in part, on the formulation and final nutritional supplement.


Preservatives may also be added to the nutritional supplement to extend product shelf life. Preferably, preservatives such as potassium sorbate, sodium sorbate, potassium benzonate, sodium benzonate or calcium disodium EDTA are used.


The nutritional supplements of embodiments of the present invention may be formulated using any pharmaceutically acceptable forms of the vitamins, minerals and other nutrients discussed above, including their salts. They may be formulated into capsules, tablets, powders, suspensions, jells or liquids optionally comprising at physiologically acceptable carrier such as but not limited to water, milk, juice, sodas, starch, vegetable oils, salt solutions, hydroxymethyl cellulose, carbohydrates.


In an embodiment, bio-nutritional supplements may be formulated as a tablet. The nutritional supplements of this invention may be formulated with other foods or liquids to provide pre-measured supplemental foods, such as a single serving bar or beverage, for example. To manufacture such a beverage, the ingredients are dried and made readily soluble in water and other consumable liquids as described above.


Several of the complex actions initiated by a stressful condition are dependent on a constant supply of certain nutrients. Lack of these nutrients often causes poor adaptation to the stressful condition and a failure to return to homeostasis. The most comprehensive work on this subject is the report from the Committee on Military Nutrition Research of the Institute of Medicine in response to the Armed Forces request for a list of nutrients that will enhance performance during stressful conditions. (Marriott B M (ed.), Food Components to Enhance Performance, Washington, D.C.: National Academy Press (1994): Committee on Military Nutrition and Research, Conclusions and Recommendations, in: Marriott B N. Food Components to Enhance Performance, Washington, D.C.: National Academy Press, 47-61, 1994)).


The active ingredients of a nutritional supplement of the present invention, as discussed in detail above, work to relieve stressful conditions and alter the mood.


Long-term administration of the nutritional supplements of the present invention may aid in the reduction of health risks associated with chronic stress, such as diminished mental and physical performance, dampened immune function, depression, hyper lididemia, cardiovascular disease, hypertension, obesity and diabetes. Regulation of serotonin and cortisol levels using the nutritional supplement in the present invention may be instrumental in reducing some of the side effects of stress.


The composition and dietary nutritional supplements of the present invention are, in one embodiment, orally administered daily. Based on the serving size of about 60 grams to about 75 grams per serving, the recommended dosage is twice daily. For example, the supplement is in the form of a tablet and the patient would consume one in the morning and one mid to late afternoon, to modulate stress and mood, which can be impaired by foods consumed at lunch. The recommended daily amounts of each ingredient, as described above, serve as a guideline for formulating the dietary supplements of this present invention. The actual amounts of each ingredient per unit dosage will depend on the number of units daily administered to the individual in need thereof. This is a matter of product design and is well within the skill of the dietary supplement formulator.


The ingredients can be administered in a single formulation or they can be separately administered. For example, it may be desirable to administer bitter tasting ingredients in the form that masks their tastes (e.g., capsule or pill form) rather than incorporating them into the nutritional composition it self (e.g., powder or bar). Thus, an embodiment of the present invention also provides a pharmaceutical pack or one or more containers filled with one or more of the ingredients of the nutritional compositions of the invention (e.g., nutritional supplement in the form of a powder and tablets).


While the invention has been particularly shown and described with reference to embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the present invention encompassed by the appended claims.

Claims
  • 1. A composition, consisting essentially of: about 750 IUs to about 1500 IUs of vitamin A, about 125 IUs to about 250 IUs of vitamin E, about 600 IUs to about 1800 IUs of vitamin D3, about 375 mg to about 750 mg of vitamin C, about 25 mg to about 50 mg of vitamin B1, about 3.4 mg to about 6.8 mg of riboflavin, about 35 mg to about 70 mg of niacin, about 1.25 mg to about 2.5 mg of folic acid, about 35 mg to about 70 mg of vitamin B6, about 75 mcg of biotin, about 5 mg to about 10 mg pantothenic acid, about 70 mcg to about 140 mcg of vitamin B12, about 35 mg to about 70 mg of magnesium, about 35 mg to about 70 mg of zinc, about 125 mcg to about 250 mcg of selenium, about 150 mcg to about 300 mcg of chromium, about 1 mg to about 2 mg of copper, about a trace amount to about 1 mg of added iron, about 10 mg to about 20 mg of alpha lipoic acid, about 350 mcg to about 700 mcg of lutein, and about 125 mcg to about 250 mcg of lycopene.
  • 2. A composition, consisting essentially of: about 750 IUs of vitamin A, about 125 IUs of vitamin E, about 1200 IUs of vitamin D3, about 375 mg of vitamin C, about 25 mg of vitamin B1, about 3.4 mg of riboflavin, about 35 mg of niacin, about 1.25 mg of folic acid, about 35 mg of vitamin B6, about 75 mcg of biotin, about 5 mg of pantothenic acid, about 70 mcg of vitamin B12, about 35 mg of magnesium, about 35 mg of zinc, about 125 mcg of selenium, about 150 mcg of chromium, about 1 mg of copper, about a trace amount of added iron, about 10 mg of alpha lipoic acid, about 350 mcg of lutein and about 125 mcg of lycopene.
  • 3. A dosing formulation of a composition, the dosing formulation comprising a single dose formulation of the composition, wherein the composition consists essentially of: about 750 IUs to about 1500 IUs of vitamin A, about 125 IUs to about 250 IUs of vitamin E, about 600 IUs to about 1800 IUs of vitamin D3, about 375 mg to about 750 mg of vitamin C, about 25 mg to about 50 mg of vitamin B1, about 3.4 mg to about 6.8 mg of riboflavin, about 35 mg to about 70 mg of niacin, about 1.25 mg to about 2.5 mg of folic acid, about 35 mg to about 70 mg of vitamin B6, about 75 mcg of biotin, about 5 mg to about 10 mg pantothenic acid, about 70 mcg to about 140 mcg of vitamin B12, about 35 mg to about 70 mg of magnesium, about 35 mg to about 70 mg of zinc, about 125 mcg to about 250 mcg of selenium, about 150 mcg to about 300 mcg of chromium, about 1 mg to about 2 mg of copper, about a trace amount to about 1 mg of added iron, about 10 mg to about 20 mg of alpha lipoic acid, about 350 mcg to about 700 mcg of lutein, and about 125 mcg to about 250 mcg of lycopene.
  • 4. The dosing formulation of claim 3, wherein the single dosage formulation is selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, an effervescent tablet, a hard gelatin capsule, and a soft gelatin capsule.
  • 5. The dosing formulation of claim 3, wherein the single dosage formulation consists essentially of an enteric coating.
  • 6. The dosing formulation of claim 3, wherein the single dosage formulation consists essentially of a liquid suspension.
  • 7. The dosing formulation of claim 3, wherein the single dosage formulation consists essentially of a food product.
  • 8. A dosing formulation of a composition, the dosing formulation comprising a single dose formulation of the composition, wherein the composition consists essentially of: about 750 IUs of vitamin A, about 125 IUs of vitamin E, about 1200 IUs of vitamin D3, about 375 mg of vitamin C, about 25 mg of vitamin B1, about 3.4 mg of riboflavin, about 35 mg of niacin, about 1.25 mg of folic acid, about 35 mg of vitamin B6, about 75 mcg of biotin, about 5 mg of pantothenic acid, about 70 mcg of vitamin B12, about 35 mg of magnesium, about 35 mg of zinc, about 125 mcg of selenium, about 150 mcg of chromium, about 1 mg of copper, about a trace amount of added iron, about 10 mg of alpha lipoic acid, about 350 mcg of lutein and about 125 mcg of lycopene in a pharmaceutically acceptable single dosage formulation.
  • 9. The dosing formulation of claim 8, wherein the single dosage formulation is selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, an effervescent tablet, a hard gelatin capsule, and a soft gelatin capsule.
  • 10. The dosing formulation of claim 8, wherein the single dosage formulation consists essentially of an enteric coating.
  • 11. The dosing formulation of claim 8, wherein the single dosage formulation consists essentially of a liquid suspension.
  • 12. The dosing formulation of claim 8, wherein the single dosage formulation consists essentially of a food product.
  • 13. A method of treating physiological conditions in response to stressful situations comprising: administering to an individual a composition consisting essentially of:about 750 IUs to about 1500 IUs of vitamin A, about 125 IUs to about 250 IUs of vitamin E, about 600 IUs to about 1800 IUs of vitamin D3, about 375 mg to about 750 mg of vitamin C, about 25 mg to about 50 mg of vitamin B1, about 3.4 mg to about 6.8 mg of riboflavin, about 35 mg to about 70 mg of niacin, about 1.25 mg to about 2.5 mg of folic acid, about 35 mg to about 70 mg of vitamin B6, about 75 mcg of biotin, about 5 mg to about 10 mg pantothenic acid, about 70 mcg to about 140 mcg of vitamin B12, about 35 mg to about 70 mg of magnesium, about 35 mg to about 70 mg of zinc, about 125 mcg to about 250 mcg of selenium, about 150 mcg to about 300 mcg of chromium, about 1 mg to about 2 mg of copper, about a trace amount to about 1 mg of added iron, about 10 mg to about 20 mg of alpha lipoic acid, about 350 mcg to about 700 mcg of lutein, and about 125 mcg to about 250 mcg of lycopene.
  • 14. A method of treating physiological conditions in response to stressful situations comprising: administering to an individual a composition consisting essentially of: about 750 IUs of vitamin A, about 125 IUs of vitamin E, about 1200 IUs of vitamin D3, about 375 mg of vitamin C, about 25 mg of vitamin B1, about 3.4 mg of riboflavin, about 35 mg of niacin, about 1.25 mg of folic acid, about 35 mg of vitamin B6, about 75 mcg of biotin, about 5 mg of pantothenic acid, about 70 mcg of vitamin B12, about 35 mg of magnesium, about 35 mg of zinc, about 125 mcg of selenium, about 150 mcg of chromium, about 1 mg of copper, about a trace amount of added iron, about 10 mg of alpha lipoic acid, about 350 mcg of lutein and about 125 mcg of lycopene.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 12/698,174, filed Feb. 2, 2010 now U.S. Pat. No. 7,901,710, entitled “Nutritional Supplement for Use under Physiologically Stressful Conditions,” which is continuation-in-part of U.S. patent application Ser. No. 11/197,757, filed Aug. 4, 2005, entitled “Nutritional Supplement for Use under Physiologically Stressful Conditions.” The disclosures of both U.S. patent application Ser. Nos. 12/698,174 and 11/197,757 are incorporated herein by reference in their entireties.

US Referenced Citations (348)
Number Name Date Kind
4582709 Peters et al. Apr 1986 A
4629625 Gaull Dec 1986 A
4752479 Briggs et al. Jun 1988 A
4786510 Nakel et al. Nov 1988 A
4786518 Nakel et al. Nov 1988 A
4812303 Iorio Mar 1989 A
4867989 Silva et al. Sep 1989 A
4973467 Sahley Nov 1990 A
4980168 Sahley Dec 1990 A
4992282 Mehansho et al. Feb 1991 A
4994283 Mehansho et al. Feb 1991 A
5051258 Sahley Sep 1991 A
5061723 Barua et al. Oct 1991 A
5151274 Saltman et al. Sep 1992 A
5223285 DeMichele et al. Jun 1993 A
5308627 Umbdenstock, Jr. May 1994 A
5312626 Gergely et al. May 1994 A
5332579 Umbdenstock Jul 1994 A
5445837 Burkes et al. Aug 1995 A
5447732 Tanimoto et al. Sep 1995 A
5468506 Andon Nov 1995 A
5494678 Paradissis et al. Feb 1996 A
5496567 McLean Mar 1996 A
5501857 Zimmer Mar 1996 A
5514382 Sultenfuss May 1996 A
5569458 Greenberg Oct 1996 A
5569459 Shlyankevich Oct 1996 A
5569477 Nesbitt Oct 1996 A
5571441 Andon et al. Nov 1996 A
5597585 Williams et al. Jan 1997 A
5612061 Rabkin Mar 1997 A
5614553 Ashmead et al. Mar 1997 A
5626883 Paul May 1997 A
5646116 Burk Jul 1997 A
5654011 Jackson et al. Aug 1997 A
5686107 Ratnaraj et al. Nov 1997 A
D393203 Saltzman et al. Apr 1998 S
5770215 Moshyedi Jun 1998 A
5807586 Jackson et al. Sep 1998 A
5869084 Paradissis et al. Feb 1999 A
5879698 Ellenbogen et al. Mar 1999 A
5922361 Bieser et al. Jul 1999 A
5922704 Bland Jul 1999 A
5935610 McLean Aug 1999 A
5948443 Riley et al. Sep 1999 A
5952317 Deluca et al. Sep 1999 A
5962030 Fine Oct 1999 A
5965162 Fuisz et al. Oct 1999 A
5976568 Riley Nov 1999 A
5976784 DeLuca et al. Nov 1999 A
5977073 Khaled Nov 1999 A
6040333 Jackson Mar 2000 A
6051236 Portman Apr 2000 A
6060093 Davis et al. May 2000 A
6080431 Andon et al. Jun 2000 A
6080788 Sole et al. Jun 2000 A
6086915 Zeligs et al. Jul 2000 A
6106874 Liebrecht et al. Aug 2000 A
6124268 Ghosal Sep 2000 A
6143300 Stevenot Nov 2000 A
6150399 Patel et al. Nov 2000 A
6150411 Stordy Nov 2000 A
6174857 Burk Jan 2001 B1
6174890 Riga et al. Jan 2001 B1
6187318 Mitchell et al. Feb 2001 B1
6190693 Kafrissen et al. Feb 2001 B1
6197329 Hermelin et al. Mar 2001 B1
6203819 Fine Mar 2001 B1
6210686 Bell et al. Apr 2001 B1
6228388 Paradissis et al. May 2001 B1
6235322 Lederman May 2001 B1
6238672 Chen May 2001 B1
6241997 Kershman et al. Jun 2001 B1
6245378 Cavazza Jun 2001 B1
6248909 Akimoto et al. Jun 2001 B1
6255341 DeMichele et al. Jul 2001 B1
6258846 Hermelin et al. Jul 2001 B1
6261600 Kirschner et al. Jul 2001 B1
6265438 Steward Jul 2001 B1
6277396 Dente Aug 2001 B1
6290974 Swaisgood et al. Sep 2001 B1
6291517 Bagchi et al. Sep 2001 B1
6291533 Fleischner Sep 2001 B1
6299886 Piper Oct 2001 B1
6299896 Cooper et al. Oct 2001 B1
6300309 Guler et al. Oct 2001 B1
6346284 Briend et al. Feb 2002 B1
6352713 Kirschner et al. Mar 2002 B1
6358544 Henry, Jr. et al. Mar 2002 B1
6358925 Guler et al. Mar 2002 B1
6361800 Cooper et al. Mar 2002 B1
6362221 Clark et al. Mar 2002 B1
6365176 Bell et al. Apr 2002 B1
6368640 Wuh et al. Apr 2002 B1
6369042 Oberthur et al. Apr 2002 B1
6372782 Patel et al. Apr 2002 B1
6410058 Gohlke et al. Jun 2002 B2
6416737 Manolagas et al. Jul 2002 B1
6420350 Fleischner Jul 2002 B1
6426097 Grose Jul 2002 B2
6432442 Buehler et al. Aug 2002 B1
6436406 Yegorova Aug 2002 B1
6436453 van Lengerich et al. Aug 2002 B1
6436910 Yerxa et al. Aug 2002 B1
6440450 Han et al. Aug 2002 B1
6444218 Han et al. Sep 2002 B2
6447809 Krumhar et al. Sep 2002 B1
6451341 Slaga et al. Sep 2002 B1
6455068 Licari Sep 2002 B1
6455714 Holick et al. Sep 2002 B1
6461652 Henry et al. Oct 2002 B1
6465013 DeBernardi Oct 2002 B1
6468568 Leusner et al. Oct 2002 B1
6475511 Gohlke et al. Nov 2002 B2
6475539 DeWille et al. Nov 2002 B1
6479545 Levinson et al. Nov 2002 B1
6485738 Huang et al. Nov 2002 B1
6488956 Paradissis et al. Dec 2002 B1
6495173 Yegorova Dec 2002 B1
6495177 deVries et al. Dec 2002 B1
6495736 Brunkow et al. Dec 2002 B1
6497885 Trant Dec 2002 B2
6497906 Kelly Dec 2002 B1
6503529 Fleischner Jan 2003 B1
6509045 Henry et al. Jan 2003 B2
6509326 Andon et al. Jan 2003 B1
6517861 Singh et al. Feb 2003 B2
6521247 deVries Feb 2003 B1
6541005 Yegorova Apr 2003 B1
6541006 Yegorova Apr 2003 B1
6544525 Yegorova Apr 2003 B1
6544563 Wuh et al. Apr 2003 B2
6562378 Chandra May 2003 B1
6565891 Chandra May 2003 B1
6569445 Manning et al. May 2003 B2
6569477 Lederman May 2003 B2
6569857 Hermelin et al. May 2003 B1
6569869 Assmann et al. May 2003 B2
6576242 Yegorova Jun 2003 B1
6576253 Manning et al. Jun 2003 B2
6576666 Hermelin et al. Jun 2003 B2
6579544 Rosenberg et al. Jun 2003 B1
6579899 Wurtman et al. Jun 2003 B1
6585998 Cartwright et al. Jul 2003 B2
6592863 Fuchs et al. Jul 2003 B2
6592909 Belcheff Jul 2003 B2
6593310 Cullis-Hill Jul 2003 B1
6596313 Rosenbloom Jul 2003 B2
6596762 Sokol Jul 2003 B2
6605646 Herbert Aug 2003 B2
6630158 Popp et al. Oct 2003 B2
6642212 Kelly Nov 2003 B1
6646013 Barker et al. Nov 2003 B1
6649195 Gorsek Nov 2003 B1
6653332 Jaen et al. Nov 2003 B2
6660293 Giordano et al. Dec 2003 B2
6667063 Crum Dec 2003 B2
6706478 Duff et al. Mar 2004 B2
6720013 Johnson et al. Apr 2004 B2
6743770 Bell et al. Jun 2004 B2
6752986 Bauer et al. Jun 2004 B2
6756401 Day et al. Jun 2004 B2
6780438 Gohlke et al. Aug 2004 B2
6790462 Hendricks Sep 2004 B2
6793935 Hermelin et al. Sep 2004 B2
6814983 Giordano et al. Nov 2004 B2
6818228 Walsdorf et al. Nov 2004 B1
6818234 Nair et al. Nov 2004 B1
6827945 Rosenbloom Dec 2004 B2
6830761 Zlotkin Dec 2004 B1
6835402 Clark et al. Dec 2004 B1
6837682 Evenson et al. Jan 2005 B2
6843372 Weinstein Jan 2005 B2
6844012 Forceville et al. Jan 2005 B1
6849274 Whittle Feb 2005 B1
6849613 Prasad et al. Feb 2005 B2
6852335 DeBernardi Feb 2005 B2
6863904 Giordano et al. Mar 2005 B2
6881419 Lovett Apr 2005 B2
6881425 Pushpangadan et al. Apr 2005 B2
6887850 Fuchs et al. May 2005 B2
6914073 Boulos et al. Jul 2005 B2
6929807 McAnalley et al. Aug 2005 B1
6953588 Cooper et al. Oct 2005 B2
6955873 Blum Oct 2005 B1
6960581 Betageri et al. Nov 2005 B2
6995166 Giordano et al. Feb 2006 B1
20010022980 Bell et al. Sep 2001 A1
20010031283 Belcheff Oct 2001 A1
20010031744 Kosbab Oct 2001 A1
20010036468 Han et al. Nov 2001 A1
20010036936 Day et al. Nov 2001 A1
20010041741 Sole et al. Nov 2001 A1
20010055623 Jackson Dec 2001 A1
20020015762 Quinlan Feb 2002 A1
20020032234 Hermelin et al. Mar 2002 A1
20020034543 Kirschner et al. Mar 2002 A1
20020037928 Jaen et al. Mar 2002 A1
20020044957 Fuchs et al. Apr 2002 A1
20020044961 Kirschner et al. Apr 2002 A1
20020044988 Fuchs et al. Apr 2002 A1
20020045184 Chen Apr 2002 A1
20020058088 Henry et al. May 2002 A1
20020064578 Henry et al. May 2002 A1
20020066691 Varon Jun 2002 A1
20020099032 Higashi et al. Jul 2002 A1
20020102330 Schramm et al. Aug 2002 A1
20020110604 Babish et al. Aug 2002 A1
20020119183 Hermelin et al. Aug 2002 A1
20020119928 McAnalley Aug 2002 A1
20020119933 Butler et al. Aug 2002 A1
20020132800 Popp et al. Sep 2002 A1
20020136711 Cochran Sep 2002 A1
20020136782 Fleischner Sep 2002 A1
20020137749 Levinson et al. Sep 2002 A1
20020146471 Wuh et al. Oct 2002 A1
20020147152 Bell et al. Oct 2002 A1
20020147153 Bell et al. Oct 2002 A1
20020150607 Schramm et al. Oct 2002 A1
20020150649 Bell Oct 2002 A1
20020155163 Benjamin et al. Oct 2002 A1
20020155181 Wuh et al. Oct 2002 A1
20020168429 Mann Nov 2002 A1
20020172721 Boulos et al. Nov 2002 A1
20020173510 Levinson et al. Nov 2002 A1
20020187205 Paradissis et al. Dec 2002 A1
20020193379 Copp et al. Dec 2002 A1
20020197330 Jackson et al. Dec 2002 A1
20030012824 Ott et al. Jan 2003 A1
20030012826 Giordano et al. Jan 2003 A1
20030013639 Yurchak et al. Jan 2003 A1
20030017205 DeBernardi Jan 2003 A1
20030031726 Hendricks Feb 2003 A1
20030044473 Fleischner Mar 2003 A1
20030059481 Krumhar et al. Mar 2003 A1
20030068372 Kirschner et al. Apr 2003 A1
20030091552 Cartwright et al. May 2003 A1
20030091613 DeWille et al. May 2003 A1
20030096018 Schloss et al. May 2003 A1
20030099730 Rosenbloom May 2003 A1
20030104050 Matharu et al. Jun 2003 A1
20030104078 Barrett-Reis et al. Jun 2003 A1
20030108594 Manning et al. Jun 2003 A1
20030108605 Hermelin et al. Jun 2003 A1
20030108624 Kosbab Jun 2003 A1
20030138484 Gianesello et al. Jul 2003 A1
20030143287 Bell Jul 2003 A1
20030147996 Prasad et al. Aug 2003 A1
20030148946 Levy et al. Aug 2003 A1
20030162807 Day et al. Aug 2003 A1
20030166247 Brunkow et al. Sep 2003 A1
20030170327 Dahl Sep 2003 A1
20030185918 Rosenbloom Oct 2003 A1
20030190355 Hermelin et al. Oct 2003 A1
20030190369 Lovett Oct 2003 A1
20030198661 Harper et al. Oct 2003 A1
20030198730 Stewart Oct 2003 A1
20030202992 Fuchs et al. Oct 2003 A1
20030203053 Wuh et al. Oct 2003 A1
20030206969 Nidamarty et al. Nov 2003 A1
20030216351 Hermelin et al. Nov 2003 A1
20030229014 Schneider et al. Dec 2003 A1
20040009535 Brunkow et al. Jan 2004 A1
20040013743 Jackson Jan 2004 A1
20040047898 Harper et al. Mar 2004 A1
20040048812 Kelly Mar 2004 A1
20040048870 Amir et al. Mar 2004 A1
20040052918 Briend et al. Mar 2004 A1
20040058321 Brunkow et al. Mar 2004 A1
20040076664 Bonura Apr 2004 A1
20040082536 Cooper et al. Apr 2004 A1
20040086574 Giordano et al. May 2004 A1
20040087515 Butler et al. May 2004 A1
20040101554 Kirschner et al. May 2004 A1
20040106561 Kelly Jun 2004 A1
20040109901 Giordano et al. Jun 2004 A1
20040140241 Weinstein Jul 2004 A1
20040162292 Evenstad et al. Aug 2004 A1
20040166175 Giordano et al. Aug 2004 A1
20040170702 VanStockum Sep 2004 A1
20040175415 Chan et al. Sep 2004 A1
20040185119 Theuer Sep 2004 A1
20040191296 Sternberg Sep 2004 A1
20040197430 Meyrowitz Oct 2004 A1
20040198674 Levy et al. Oct 2004 A1
20040209848 Maruyama et al. Oct 2004 A1
20040213857 Soldati et al. Oct 2004 A1
20040213873 Parvez Oct 2004 A1
20040219235 Pushpangadan et al. Nov 2004 A1
20040220118 Bland et al. Nov 2004 A1
20040224032 Zlotkin Nov 2004 A1
20040228931 Chokshi et al. Nov 2004 A1
20040234544 Jager et al. Nov 2004 A1
20040234579 Finke Nov 2004 A1
20040235728 Stoch et al. Nov 2004 A1
20040254095 Martin et al. Dec 2004 A1
20040259886 Day et al. Dec 2004 A1
20050009835 Thomas Jan 2005 A1
20050016893 Nakagawa et al. Jan 2005 A1
20050026223 Manolagas et al. Feb 2005 A1
20050032741 Venkataraman Feb 2005 A1
20050037065 Kirschner et al. Feb 2005 A1
20050058671 Bedding et al. Mar 2005 A1
20050059641 Ray et al. Mar 2005 A1
20050069608 Hendricks Mar 2005 A1
20050095262 Camponovo et al. May 2005 A1
20050100613 Giordano et al. May 2005 A1
20050101670 Hermelin et al. May 2005 A1
20050106266 Levinson et al. May 2005 A1
20050112176 Dopson et al. May 2005 A1
20050112177 Dopson et al. May 2005 A1
20050112211 Gervais et al. May 2005 A1
20050119218 Prasad et al. Jun 2005 A1
20050123628 Zabrecky Jun 2005 A1
20050130933 Jacobs et al. Jun 2005 A1
20050142124 Kaiser Jun 2005 A1
20050143357 Pousette et al. Jun 2005 A1
20050153019 Fuchs et al. Jul 2005 A1
20050171034 Halevie-Goldman Aug 2005 A1
20050186252 Ahlgren et al. Aug 2005 A1
20050187144 Fine et al. Aug 2005 A1
20050196343 Reddy et al. Sep 2005 A1
20050196434 Brierre Sep 2005 A1
20050196469 Thys-Jacobs Sep 2005 A1
20050214383 Bubnis et al. Sep 2005 A1
20050214388 Gorham et al. Sep 2005 A1
20050226942 Myhill et al. Oct 2005 A1
20050233946 Fine et al. Oct 2005 A1
20050233947 Fine et al. Oct 2005 A1
20050249787 Reynolds et al. Nov 2005 A1
20050249788 Reynolds et al. Nov 2005 A1
20050256178 Eggersdorfer et al. Nov 2005 A1
20050260284 DiMateeo-Leggio Nov 2005 A1
20050261172 Schneider et al. Nov 2005 A1
20050261257 Vermeer Nov 2005 A1
20050281888 Chandra Dec 2005 A1
20050281889 Chandra Dec 2005 A1
20050282794 Fine et al. Dec 2005 A1
20050287228 Trant Dec 2005 A1
20060003981 Fine et al. Jan 2006 A1
20060008543 Myhill et al. Jan 2006 A1
20060008544 Myhill et al. Jan 2006 A1
20060018975 Talbott Jan 2006 A1
20060024384 Giordano Feb 2006 A1
20060024409 Giordano Feb 2006 A1
20060034912 Giordano et al. Feb 2006 A1
20060034916 Giordano et al. Feb 2006 A1
20060160753 Cassidy et al. Jul 2006 A1
Related Publications (1)
Number Date Country
20110159055 A1 Jun 2011 US
Continuations (1)
Number Date Country
Parent 12698174 Feb 2010 US
Child 13043133 US
Continuation in Parts (1)
Number Date Country
Parent 11197757 Aug 2005 US
Child 12698174 US